- June 01, 2020
A Radiologist and an Artist: Boustani Provides High Quality Medical Illustrations for Her Peers
- August 22, 2019
Yale Radiology Medical Student Thesis Program Annual Update
- August 22, 2019
Yale Radiologists Advance Prostate Cancer Imaging
- May 09, 2019
2019 Honors & Achievements
- January 23, 2019
Imaging Agent Shows Promise for Better Prostate Cancer Detection
- July 16, 2018
Yale-developed test for Alzheimer’s disease directly measures synaptic loss
Nuclear Medicine
General Information
PO Box 208042
New Haven, CT 06520-8042 Admin Assistant, Nel Rodríguez |
Phone:
|
203-785-7384
|
The Nuclear Medicine section in the Department of Radiology and Biomedical Imaging is comprised of subspecialty trained physicians. The section provides comprehensive nuclear medicine imaging and therapy.
Clinical
Nuclear medicine uses organ function to image and treat many diseases. Small amounts of radioactive substances are administered to patients to map organ function and create functional or molecular images.
Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) are nuclear medicine techniques used to generate highly sensitive, measurable images of disease.
Examples of nuclear medicine studies include imaging for pulmonary embolism, infection, gastrointestinal bleeding, renal function, bone tumors, fractures, gallbladder diseases, Parkinson's disease, hyperparathyroidism, thyroid diseases, neuroendocrine diseases, dementia, epilepsy and many forms of cancer.
We have an active nuclear medicine therapy service, treating thyroid cancer and hyperthyroidism, as well as metastatic disease. The Nuclear Medicine Section was the first site in Connecticut to use Ra-223 therapy for bone pain palliation in patients with metastatic prostate cancer. Patients receiving treatment doses are seen by physicians in our nuclear medicine consultation clinic, where we discuss treatment effects and radiation safety precautions.
New additions to the Nuclear Medicine division include state-of-the-art PET/CT scanners for evaluation of cancer and neurologic diseases. We have 3 dedicated PET/CT scanners which provide the highest quality molecular imaging for tumor diagnosis, staging and treatment response.
The Nuclear Medicine section is at the forefront of the field of theranostics. Theranostics is the term used to describe the combination of using one radioactive agent to diagnose disease and a second radioactive drug to deliver therapy to treat tumors. We were the first site in Connecticut to utilize this technology in the imaging and treatment of neuroendocrine tumors.
Research
The section of Nuclear Medicine is actively involved in performing clinical and translational research. Some recent examples include novel PET agents for imaging and treating prostate and neuroendocrine cancers and the imaging of brain tumors. The Molecular Imaging Clinical and Translational Research Laboratory (MICTRL) was created to support the rapid growth of our involvement in this arena.
The research mission of the section is realized through collaboration with the Yale Positron Emission Tomography Center (PET Center). The PET Center provides the highest quality nuclear imaging research to aid in the diagnosis of disease and advance drug development.
Education
The Nuclear Medicine section is committed to the strong education mission embraced by the Department of Radiology and Biomedical Imaging. This includes daily clinical rotation teaching, multidisciplinary conferences and didactic lectures for medical students, radiology residents and nuclear radiology fellows.
The section has an ACGME accredited Nuclear Radiology Fellowship, as well as the Nuclear Radiology Pathway. Through the American Board of Radiology, the Nuclear Radiology Pathway enables diagnostic radiology residents to qualify for dual board certification in Radiology and Nuclear Medicine.
Recent Publications
2023
- PET/MRI Applications in Pediatric Epilepsy.Pedersen C, Aboian M, Messina SA, Daldrup-Link H, Franceschi AM. World J Nucl Med. 2023 Jun; 2023 Apr 28. PMID: 37223623.
- The role of imaging and sentinel lymph node biopsy in patients with T3b-T4b melanoma with clinically negative disease.Papageorge MV, Maina RM, King ALO, Lee V, Baumann R, Pucar D, Ariyan S, Khan SA, Weiss SA, Clune J, Olino K. Front Oncol. 2023; 2023 May 8. PMID: 37223678.
- Comparison of whole-body DW-MRI with 2-[(18)F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis.Baratto L, Nyalakonda R, Theruvath AJ, Sarrami AH, Hawk KE, Rashidi A, Shen S, States L, Aboian M, Jeng M, Daldrup-Link HE. Eur J Nucl Med Mol Imaging. 2023 May; 2023 Jan 31. PMID: 36717409.
- Artificial Intelligence for Neuroimaging and Musculoskeletal Radiology: Overview of Current Commercial Algorithms.Berson ER, Aboian MS, Malhotra A, Payabvash S. Semin Roentgenol. 2023 Apr; 2023 Mar 31. PMID: 37087138.
- Automated tumor segmentation and brain tissue extraction from multiparametric MRI of pediatric brain tumors: A multi-institutional study.Fathi Kazerooni A, Arif S, Madhogarhia R, Khalili N, Haldar D, Bagheri S, Familiar AM, Anderson H, Haldar S, Tu W, Chul Kim M, Viswanathan K, Muller S, Prados M, Kline C, Vidal L, Aboian M, Storm PB, Resnick AC, Ware JB, Vossough A, Davatzikos C, Nabavizadeh A. Neurooncol Adv. 2023 Jan-Dec; 2023 Mar 16. PMID: 37051331.
- ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer.Li Z, Belitzky E, Blaha O, Cavaliere A, Katz SR, Aboian M, Melegari L, Rajabimoghadam K, Kurpiewski S, Zhu X, Marquez-Nostra B. Cancers (Basel). 2023 Mar 3; 2023 Mar 3. PMID: 36900378.
- Comparing 3D, 2.5D, and 2D Approaches to Brain Image Auto-Segmentation.Avesta A, Hossain S, Lin M, Aboian M, Krumholz HM, Aneja S. Bioengineering (Basel). 2023 Feb 1; 2023 Feb 1. PMID: 36829675.
- Brain PET Imaging: Approach to Cognitive Impairment and Dementia.Spano M, Roytman M, Aboian M, Saboury B, Franceschi A, Chiang GC. PET Clin. 2023 Jan. PMID: 36442959.
- Spectrum of qualitative and quantitative imaging of pilomyxoid, intermediate pilomyxoid and pilocytic astrocytomas in relation to their genetic alterations.Fadel SA, von Reppert M, Kazarian E, Omay EZE, Marks A, Linder N, Hoffmann KT, Darbinyan A, Huttner A, Aboian MS. Neuroradiology. 2023 Jan; 2022 Aug 19. PMID: 35984480.
2022
- Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [(11) C]UCB-J.Mecca AP, O'Dell RS, Sharp ES, Banks ER, Bartlett HH, Zhao W, Lipior S, Diepenbrock NG, Chen MK, Naganawa M, Toyonaga T, Nabulsi NB, Vander Wyk BC, Arnsten AFT, Huang Y, Carson RE, van Dyck CH. Alzheimers Dement. 2022 Dec; 2022 Feb 17. PMID: 35174954.
- FDG PET vascular imaging in IgG4-RD: Potential and challenges.Pucar D, Hinchcliff M. J Nucl Cardiol. 2022 Dec; 2021 Dec 28. PMID: 34964084.
- Real-world assessment of the clinical utility of whole body 18F-FDG PET/CT in the diagnosis of infection.Medvedeva N, Radcliffe C, Malinis M, Chen MK, Azar MM. PLoS One. 2022; 2022 Nov 14. PMID: 36374789.
- Drug characteristics derived from kinetic modeling: combined (11)C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A.Naganawa M, Gallezot JD, Finnema SJ, Maguire RP, Mercier J, Nabulsi NB, Kervyn S, Henry S, Nicolas JM, Huang Y, Chen MK, Hannestad J, Klitgaard H, Stockis A, Carson RE. EJNMMI Res. 2022 Nov 8; 2022 Nov 8. PMID: 36346513.
- Systemic inflammation enhances stimulant-induced striatal dopamine elevation in tobacco smokers.Zakiniaeiz Y, Hoye J, Ryan Petrulli J, LeVasseur B, Stanley G, Gao H, Najafzadeh S, Ropchan J, Nabulsi N, Huang Y, Chen MK, Matuskey D, Barron DS, Kelmendi B, Fulbright RK, Hampson M, Cosgrove KP, Morris ED. Brain Behav Immun. 2022 Nov; 2022 Sep 1. PMID: 36058419.
- Nicotine Patch Alters Patterns of Cigarette Smoking-Induced Dopamine Release: Patterns Relate to Biomarkers Associated With Treatment Response.Zakiniaeiz Y, Liu H, Gao H, Najafzadeh S, Ropchan J, Nabulsi N, Huang Y, Matuskey D, Chen MK, Cosgrove KP, Morris ED. Nicotine Tob Res. 2022 Oct 17. PMID: 35100429.
- Clinical implementation of artificial intelligence in neuroradiology with development of a novel workflow-efficient picture archiving and communication system-based automated brain tumor segmentation and radiomic feature extraction.Aboian M, Bousabarah K, Kazarian E, Zeevi T, Holler W, Merkaj S, Cassinelli Petersen G, Bahar R, Subramanian H, Sunku P, Schrickel E, Bhawnani J, Zawalich M, Mahajan A, Malhotra A, Payabvash S, Tocino I, Lin M, Westerhoff M. Front Neurosci. 2022; 2022 Oct 13. PMID: 36312024.
- Virtual high-count PET image generation using a deep learning method.Liu J, Ren S, Wang R, Mirian N, Tsai YJ, Kulon M, Pucar D, Chen MK, Liu C. Med Phys. 2022 Sep; 2022 Aug 13. PMID: 35880541.
- Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery.Cassinelli Petersen G, Bousabarah K, Verma T, von Reppert M, Jekel L, Gordem A, Jang B, Merkaj S, Abi Fadel S, Owens R, Omuro A, Chiang V, Ikuta I, Lin M, Aboian MS. Neurooncol Adv. 2022 Jan-Dec; 2022 Jul 26. PMID: 36043121.
- Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 2: Inflammation, Fibrosis, Thrombosis, Calcification, and Amyloidosis Imaging.Stendahl JC, Kwan JM, Pucar D, Sadeghi MM. J Nucl Med. 2022 Jul. PMID: 35772956.
- Deep learning-based attenuation correction for whole-body PET - a multi-tracer study with (18)F-FDG, (68) Ga-DOTATATE, and (18)F-Fluciclovine.Toyonaga T, Shao D, Shi L, Zhang J, Revilla EM, Menard D, Ankrah J, Hirata K, Chen MK, Onofrey JA, Lu Y. Eur J Nucl Med Mol Imaging. 2022 Jul; 2022 Mar 12. PMID: 35277742.